{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:27:40Z","timestamp":1788460060913,"version":"build-2803163510"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Gram-positive sepsis remains a leading cause of morbidity and mortality in neonates. Vancomycin is the standard of care, yet drug monitoring challenges and rising resistance demand alternatives. Daptomycin has potent bactericidal activity, low resistance development and high efficacy in biofilm-associated infections. Experience in the neonatal period is scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This retrospective study focuses on infants with confirmed Gram-positive infection admitted between January 2019 and December 2024. All patients received daptomycin (6\u2009mg\/kg every 12 hours) after vancomycin treatment failure or contraindication due to side effects. Demographic, microbiologic, antibiotic treatment features, adverse events and neonatal outcome data were extracted from the infants\u2019 medical records.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Fifty-three infants (median gestational age 29 weeks; interquartile range [IQR] 25\u201337.5) received daptomycin.\n                      <jats:italic toggle=\"yes\">Staphylococcus epidermidis<\/jats:italic>\n                      accounted for 77.4% of isolates; 90% were methicillin-resistant. Median vancomycin exposure before antibiotic switch was 5 days. Blood cultures cleared in 47\/52 assessable episodes (90.4%) after a median of 4 days on daptomycin; 1 additional case required adjunctive linezolid. Liver enzyme elevations occurred in 24% of infants, and a self-limited rash occurred in 2%; all were transient and resolved without treatment discontinuation. No muscular or neurologic toxicity was observed. Overall mortality was 24.5% (13\/53), but infection-attributable mortality was confined to 4 cases (7.5%); no infection-related deaths occurred after 2020.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In this neonatal cohort, which included a high proportion of very preterm infants, daptomycin achieved rapid microbiologic clearance and was generally well tolerated, although liver enzyme elevations were observed in approximately 1 of 4 patients. These findings support its potential role as an alternative when vancomycin fails or cannot be used. Earlier use in high-risk, catheter-associated infections merits prospective evaluation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000005136","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T05:00:12Z","timestamp":1767157212000},"page":"610-615","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Safety of Daptomycin in the Neonatal Population"],"prefix":"10.1097","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0706-4421","authenticated-orcid":false,"given":"Celia","family":"Permuy","sequence":"first","affiliation":[{"name":"Neonatology Department, La Paz University Hospital, Madrid, Spain"},{"name":"La Paz University Hospital Research Institute (IdiPaz), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jone","family":"Ruiz-Azc\u00e1rate","sequence":"additional","affiliation":[{"name":"Neonatology Department, La Paz University Hospital, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"S\u00e1nchez Garc\u00eda","sequence":"additional","affiliation":[{"name":"Neonatology Department, La Paz University Hospital, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8756-7020","authenticated-orcid":false,"given":"Teresa","family":"del Rosal","sequence":"additional","affiliation":[{"name":"La Paz University Hospital Research Institute (IdiPaz), Madrid, Spain"},{"name":"Pediatric and Infectious Diseases Department, La Paz University Hospital, Madrid, Spain"},{"name":"Pediatric Microbiology & Infectious Diseases Research Group, Center for Biomedical Network Research on Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Jim\u00e9nez","sequence":"additional","affiliation":[{"name":"Pharmacy Department, La Paz University Hospital, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iker","family":"Falces","sequence":"additional","affiliation":[{"name":"La Paz University Hospital Research Institute (IdiPaz), Madrid, Spain"},{"name":"Pediatric Microbiology & Infectious Diseases Research Group, Center for Biomedical Network Research on Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain"},{"name":"Microbiology Department, La Paz University Hospital, Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6503-3423","authenticated-orcid":false,"given":"Cristina","family":"Calvo","sequence":"additional","affiliation":[{"name":"La Paz University Hospital Research Institute (IdiPaz), Madrid, Spain"},{"name":"Pediatric and Infectious Diseases Department, La Paz University Hospital, Madrid, Spain"},{"name":"Pediatric Microbiology & Infectious Diseases Research Group, Center for Biomedical Network Research on Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelina","family":"Pellicer","sequence":"additional","affiliation":[{"name":"Neonatology Department, La Paz University Hospital, Madrid, Spain"},{"name":"La Paz University Hospital Research Institute (IdiPaz), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,31]]},"reference":[{"key":"R1-20260609","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3390\/antibiotics10020168","article-title":"Safety and efficacy of daptomycin in neonates with coagulase-negative staphylococci: case series analysis.","volume":"10","author":"Mohzari","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"R2-20260609","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1097\/INF.0000000000001570","article-title":"Late-onset sepsis in extremely premature infants: 2000\u20132011.","volume":"36","author":"Greenberg","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"R3-20260609","doi-asserted-by":"crossref","first-page":"e0164397","DOI":"10.1371\/journal.pone.0164397","article-title":"Genomic epidemiology of methicillin-resistant Staphylococcus aureus in a neonatal intensive care unit.","volume":"11","author":"Azarian","year":"2016","journal-title":"PLoS One"},{"key":"R4-20260609","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0732-8893(99)00124-8","article-title":"Biofilm production by Staphylococcus epidermidis isolates associated with catheter-related bacteremia.","volume":"36","author":"Vogel","year":"2000","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R5-20260609","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1099\/jmm.0.001117","article-title":"Methicillin-resistant Staphylococcus epidermidis isolates with reduced vancomycin susceptibility from bloodstream infections in a neonatal intensive care unit.","volume":"69","author":"Peixoto","year":"2020","journal-title":"J Med Microbiol"},{"key":"R6-20260609","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/jac\/49.3.467","article-title":"In vitro bactericidal activity of daptomycin against staphylococci.","volume":"49","author":"Fuchs","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"R7-20260609","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1128\/AAC.00824-07","article-title":"Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells.","volume":"51","author":"Mascio","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"R8-20260609","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.jiac.2016.08.011","article-title":"Risk factors for persistent bacteremia in infants with catheter-related bloodstream infection due to coagulase-negative Staphylococcus in the neonatal intensive care unit.","volume":"22","author":"Furuichi","year":"2016","journal-title":"J Infect Chemother"},{"key":"R9-20260609","doi-asserted-by":"crossref","first-page":"e0126422","DOI":"10.1128\/aac.01264-22","article-title":"Effectiveness of several antimicrobial locks to eradicate intravascular catheter coagulase-negative staphylococci biofilms.","volume":"67","author":"Blanco-Di Matteo","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"R10-20260609","doi-asserted-by":"crossref","first-page":"e01777","DOI":"10.1128\/AAC.01777-17","article-title":"High-dose daptomycin is effective as an antibiotic lock therapy in a rabbit model of Staphylococcus epidermidis catheter-related infection.","volume":"62","author":"Basas","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R11-20260609","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ijantimicag.2010.03.015","article-title":"Efficacy and safety of daptomycin in the treatment of Gram-positive catheter-related bloodstream infections in cancer patients.","volume":"36","author":"Chaftari","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"R12-20260609","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.ijantimicag.2014.01.018","article-title":"Daptomycin activity tested against 164,457 bacterial isolates from hospitalized patients: summary of 8 years of a worldwide surveillance programme (2005\u20132012).","volume":"43","author":"Sader","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"R13-20260609","first-page":"175","article-title":"Key potentially inappropriate drugs in pediatrics: the KIDs list.","volume":"25","author":"Meyers","year":"2020","journal-title":"J Pediatr Pharmacol Ther"},{"key":"R14-20260609","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/INF.0000000000001926","article-title":"Randomized multicenter study comparing safety and efficacy of daptomycin versus standard-of-care in pediatric patients with staphylococcal bacteremia.","volume":"37","author":"Arrieta","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"R15-20260609","first-page":"450","article-title":"Daptomycin experience in the pediatric and neonatal population: a systematic review.","volume":"30","author":"Yarsley","year":"2025","journal-title":"J Pediatr Pharmacol Ther"},{"key":"R16-20260609","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists.","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"R17-20260609","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1055\/s-0029-1243370","article-title":"Daptomycin use in a neonate: serum level monitoring and outcome.","volume":"27","author":"Sarafidis","year":"2010","journal-title":"Am J Perinatol"},{"key":"R18-20260609","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/phar.1872","article-title":"Clinical experience with daptomycin in pediatrics.","volume":"37","author":"Namtu","year":"2017","journal-title":"Pharmacotherapy"},{"key":"R19-20260609","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3390\/antibiotics13030254","article-title":"Daptomycin use for persistent coagulase-negative staphylococcal bacteremia in a neonatal intensive care unit.","volume":"13","author":"Papachatzi","year":"2024","journal-title":"Antibiotics (Basel)"},{"key":"R20-20260609","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3390\/children9040457","article-title":"Daptomycin for treatment of S. epidermidis endocarditis in an extremely preterm neonate: outcome and perspectives.","volume":"9","author":"Minotti","year":"2022","journal-title":"Children"},{"key":"R21-20260609","first-page":"476","article-title":"Challenges of vancomycin dosing and therapeutic monitoring in neonates.","volume":"25","author":"Pham","year":"2020","journal-title":"J Pediatr Pharmacol Ther"},{"key":"R22-20260609","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3233\/JPI-120359","article-title":"Use of daptomycin in neonates: a case report and review of the literature.","volume":"07","author":"Aswani","year":"2012","journal-title":"J Pediatr Infect Dis"},{"key":"R23-20260609","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/INF.0000000000001121","article-title":"Daptomycin for children in clinical practice experience.","volume":"35","author":"Garazzino","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"R24-20260609","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/INF.0b013e318160edfc","article-title":"Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections.","volume":"27","author":"Abdel-Rahman","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"R25-20260609","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1093\/jpids\/piw048","article-title":"Clinical effectiveness, safety profile, and pharmacokinetics of daptomycin in pediatric patients: a systematic review.","volume":"5","author":"Spyridon","year":"2016","journal-title":"J Ped Infect Dis Soc"},{"key":"R26-20260609","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s15010-011-0240-3","article-title":"Serum levels of daptomycin in pediatric patients.","volume":"40","author":"Antachopoulos","year":"2012","journal-title":"Infection"},{"key":"R27-20260609","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1097\/INF.0b013e31825d2fa2","article-title":"Pharmacokinetics and tolerability of single-dose daptomycin in young infants.","volume":"31","author":"Cohen-Wolkowiez","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"R28-20260609","first-page":"61","article-title":"Successful use of daptomycin in a preterm neonate with persistent methicillin-resistant Staphylococcus epidermidis bacteremia.","volume":"20","author":"Gawronski","year":"2015","journal-title":"J Pediatr Pharmacol Ther"},{"key":"R29-20260609","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/jcph.1576","article-title":"Pharmacokinetic\/pharmacodynamic analysis of daptomycin against Staphylococcus aureus and Enterococcus faecium in pediatric patients by Monte Carlo simulation.","volume":"60","author":"Wei","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"R30-20260609","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/INF.0000000000000318","article-title":"Single-dose pharmacokinetics of daptomycin in pediatric patients 3-24 months of age.","volume":"33","author":"Bradley","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"R31-20260609","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/INF.0000000000000962","article-title":"Use of daptomycin in critically ill children with bloodstream infections and complicated skin and soft-tissue infections.","volume":"35","author":"Tedeschi","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"R32-20260609","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1177\/00099228241242186","article-title":"Safety and treatment outcomes of infants and children treated with daptomycin: six-year experience from a pediatric academic medical center.","volume":"64","author":"Vonasek","year":"2025","journal-title":"Clin Pediatr (Phila)"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000005136","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:46:39Z","timestamp":1786034799000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000005136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000005136","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,31]]}}}